**Abstract**

Novel antiparkinsonian drug Hemantane (N-2-adamantyl hexamethylenimine hydrochloride) (H) was synthesizied and preclinically studied in Zakusov Institute of Pharmacology. Effects of H were proved in animal models of parkinsonism and in pilot clinical study in patients with early Parkinson's disease (PD). At present randomized double-blind placebo-controlled study efficacy and safety of H was evaluated in PD patients.

60 patients with initially diagnosed untreated PD were included. 20 were treated by H 25 mg daily for 16 weeks, 20 received H 25 mg during first 4 weeks and then the dose was increased to 50 mg (25 mg twice a day), 20 patient received placebo (1 or 2 tablets). Efficacy was assessed in Unified Parkinson's Disease Rating Scale (UPDRS) and several other scales. General state, blood pressure, electrocardiogram, blood and urine tests were controlled for safety evaluation.

H was more effective in patients which received 50 mg a day. The decrease of rigidity was more pronounced. In the group "H 50 mg" at the end of treatment index of rigidity was decreased by 41% to the baseline. In the group "H 50 mg" significant decrease in the score of UPDRS III "Motor examination" compared to "Placebo" group was revealed on 8, 12 and 16 weeks, the same as decrease of the total score of the scale. After 16 weeks of treatment significant difference in the total UPDRS score was registered also between "H 50 mg" and "H 25 mg" groups.

The safety of H was proved. Non serious adverse reactions were registered in 10 patients, only 6 were possibly connected with treatment, transient and did not require discontinuation of treatment.

The present study confirmed moderate efficacy of H 50 mg monotherapy in patients with early PD and safety of both daily doses. Clinical trial of H combination with dopamine agonists was recommended.
